Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
13 Juni 2008 - 6:04PM
PR Newswire (US)
VANCOUVER, June 13 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced the market launch of Quill(TM) SRS MONODERM(TM). The
product will be available immediately for distribution and sale in
the U.S. and Europe. Quill(TM) SRS MONODERM(TM), which is made from
a rapidly resorbing polymer, is intended primarily for superficial
wound closure applications and indicated for soft tissue
approximation where use of an absorbable suture is appropriate.
"The launch of MONODERM(TM) is another example of the progress we
have made in expanding the Quill(TM) SRS product line," said Dr.
William Hunter, President and CEO of Angiotech. "MONODERM(TM) is
intended primarily for skin closure and will complement Quill(TM)
SRS which currently targets deeper layers of wound closure."
Forward Looking Statements -------------------------- Statements
contained in this press release that are not based on historical
fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities
legislation. Forward-looking statements may involve, but are not
limited to, comments with respect to our strategies or future
actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research
development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or
our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; adverse
results or unexpected delays in drug discovery and clinical
development processes; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development, to expand commercialization activities or
consummate acquisitions or to service or repay debt obligations;
the accuracy of our estimations of the size of the market, and the
potential market, for our products in specific disease areas; sales
numbers and future guidance publicly provided by Boston Scientific
Corporation regarding sales of their paclitaxel-eluting coronary
stent products; and any other factors that may affect performance.
In addition, our business is subject to certain operating risks
that may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from
our actual results. These operating risks include: our ability to
attract and retain qualified personnel; our ability to successfully
complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston
Scientific Corporation to successfully manufacture, market and sell
their paclitaxel-eluting coronary stent products; the continued
availability of capital to finance our activities; our ability to
achieve the financial benefits expected as a result of the
acquisition of American Medical Instruments Holdings, Inc.; and any
other factors referenced in our annual information form and other
filings with the applicable Canadian securities regulatory
authorities or the Securities and Exchange Commission. Given these
uncertainties, assumptions and risk factors, readers are cautioned
not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained in this press release to reflect future
results, events or developments. Quill(TM) is a trademark of Quill
Medical, Inc., a wholly-owned subsidiary of Angiotech
Pharmaceuticals, Inc. (C)2008 Angiotech Pharmaceuticals, Inc. All
Rights Reserved. MONODERM(TM) is a trademark of Surgical
Specialties Corporation, a wholly-owned subsidiary of Angiotech
Pharmaceuticals, Inc. About Angiotech Angiotech Pharmaceuticals,
Inc. is a global specialty pharmaceutical and medical device
company with over 1,500 dedicated employees. Angiotech discovers,
develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. CONTACT: Deirdre Neary, Manager,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Deirdre Neary, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024